ClinicalTrials.gg
CompletedNCT01480765Updated Nov 5, 2024

Preventing Pain After Heart Surgery

A Phase 4 interventional study of Pregabalin and Ketamine infusion in Pain, Hyperalgesia and Chronic Illness, sponsored by Barts & The London NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Primary conditionNeuralgiaRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neuralgia
Why
  1. The study's listed conditions name Neuralgia, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Barts & The London NHS Trust · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The use of pre-emptive analgesia to prevent pain following sternotomy for cardiac surgery

02

Conditions studied

  • Pain
  • Hyperalgesia
  • Chronic Illness
  • Neuropathic Pain

Browse trials for

03

In context

Neuralgia Reclassified

1,100 studies on the registry are indexed under Neuralgia; 241 are open to participants now.

This study's enrollment of 150 is above the median of 52 across 831 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

Barts & The London NHS Trust is the lead sponsor of 151 studies on the registry; 21 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First time sternotomy for all cardiac surgery
  • Patient aged 18 - 80 years

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery (decision to operate taken on the day of surgery)
  • Previous sternotomy
  • Preoperative renal failure ( \<60 ml/min)
  • History of chronic non-anginal pain
  • Chronic pain medication other than paracetamol and non-steroidal anti-inflammatory drugs
  • Concurrent use of oxycodone, lorazepam, or ethanol.
  • Concurrent use of any drugs for neuropathic pain e.g. antiepileptics, antidepressants
  • Allergy to pregabalin, gabapentin or ketamine
  • Pregnancy
  • Limited understanding of numerical scoring scales
  • Previous participation in other trials investigating analgesic agents or any IMP in previous three months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Placebo comparator
    Control: Placebo + Placebo

    Placebo capsules and Placebo infusion

    Drug: Placebo capsules · Drug: Placebo infusion

  • Active comparator
    Pregabalin and Placebo infusion

    Pregabalin capsules and Placebo infusion

    Drug: Pregabalin · Drug: Placebo infusion

  • Active comparator
    Pregabalin + Ketamine infusion

    Pregabalin capsules + Ketamine infusion

    Drug: Pregabalin · Drug: Ketamine infusion

Interventions

  • 150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days

  • 0.1mg/kg/hr for 48 hours post operatively

  • DrugPlacebo capsules

    Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days

  • DrugPlacebo infusion

    Normal saline placebo intravenous infusion for 48 hours

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) pain score (around sternotomy incision site) post surgery, at rest and following 3 maximal coughs.

    Time frame: 3 and 6 months post sternotomy

Secondary outcomes

  1. Total morphine consumption at 24 hours post surgery

    Time frame: 24 hours post surgery

  2. Visual Analogue Scale (VAS) scores at 24 hrs post surgery, at rest and following 3 maximal coughs

    Time frame: 24 hours post surgery

  3. Sedation (including pCO2) and nausea scores at 24 hours post surgery

    Time frame: 24 hours post surgery

  4. Side effect episodes (dizziness, confusion, blurred vision)

    Time frame: First 48 hours

  5. Time to extubation

    Time frame: Post op recovery period

  6. Length of stay in intensive care and hospital

    Time frame: Post operative - acute

  7. 28 day mortality

    Time frame: 28 days post surgery

  8. Neuropathic pain score

    S-LANSS (Short form Leeds Assessment of Neuropathic Symptoms and Signs)

    Time frame: 3 and 6 months post surgery

  9. Quality of Life

    EQ-5D validated scoring scale

    Time frame: 3 and 6 months

  10. Survival

    Time frame: 3 and 6 months

  11. QST measurements

    Pain Pressure Thresholds (PPT) using algometry, both pre and post Diffuse Noxious Inhibitory Control (DNIC) Tactile and Pain Detection Thresholds with mechanical static stimulus using Von Frey hairs (VFH) Dynamic assessment of temporal summation and secondary hyeralgesia with VFH

    Time frame: Pre op and post op at 72hrs and 3 months

07

Study locations

1 site
  • Pain and Ananesthesia Research Centre, Barts and The London NHS Trust
    London, EC1A 7BE, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01480765
Responsible party
Sponsor
First posted
Nov 29, 2011
Start date
Dec 12, 2011
Primary completion
Mar 7, 2013
Completion
Mar 7, 2013
Last update
Nov 5, 2024

Study contacts

Sibtain Anwar, MA MB FRCA
study director · Barts and The London NHS Trust

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Ketamine

Start the discussion